Dynamics of Nigral Iron Accumulation in Parkinson's Disease: From Diagnosis to Late Stage.
Dynamics of Nigral Iron Accumulation in Parkinson's Disease: From Diagnosis to Late Stage.
复制标题
DOI：
10.1002/mds.29062
复制
发表时间：
2022-08
影响因子：
8.6
通讯作者：
Huang, Xuemei
中科院分区：
文献类型：
--
作者：
Du, Guangwei;Wang, Ernest;Sica, Christopher;Chen, Hairong;De Jesus, Sol;Lewis, Mechelle M.;Kong, Lan;Connor, James;Mailman, Richard B.;Huang, Xuemei
据报道，帕金森病（PD）患者的黑质铁含量较高。了解PD患者体内铁积累的动态变化及其与药物治疗的关系。79名对照组、18名drug-naïve （PDDN）和87名药物治疗（PDDT）受试者获得了敏感性MRI数据。用定量易感性图估计基底节区和小脑结构的脑铁。以病程定义的PDDN和PDDT亚组之间的黑质铁比较[早期（PDE, <2年），中期（PDM， 2-6年），晚期（PDL， bb0 -6年）]。使用回归分析探讨与疾病持续时间和抗帕金森药物类型的关系。与对照组相比，PDDN在黑质（p=0.018）、尾状核（p=0.038）和苍白球（p=0.01）中铁含量较低，但在壳核和红核中铁含量较低。相比之下，与对照组或PDDN相比，PDDT在黑质中含有更高的铁（p < 0.001），但在其他区域则没有。黑质铁随着病程的延长而增加[PDE > PDDN (p=0.001), PDM > PDE (p=0.045)]，但PDM vs PDL （p=0.226）除外。左旋多巴的使用与较高的黑质铁相关（p=0.013），而较低的黑质铁与selegiline的使用相关（p= 0.030）。在开始服用多巴胺能药物之前，黑质铁含量较低，然后在整个疾病过程中增加，直到晚期达到稳定水平，这表明铁含量增加可能不是病因。有趣的是，PD药物可能与铁积累有不同的关联，值得进一步研究。
Higher nigral iron has been reported in Parkinson’s disease (PD). To understand the dynamics of nigral iron accumulation in PD and its association with drug treatment. Susceptibility MRI data was obtained from 79 control, 18 drug-naïve (PDDN), and 87 drug-treated (PDDT) subjects. Regional brain iron in basal ganglia and cerebellar structures was estimated using quantitative susceptibility mapping. Nigral iron was compared among PDDN and PDDT subgroups defined by disease duration [early (PDE, <2 years), middle (PDM, 2-6 years), later (PDL, >6 years)]. Associations with both disease duration and types of antiparkinson drugs were explored using regression analysis. Compared to controls, PDDN had lower iron in the substantia nigra (p=0.018), caudate nucleus (p=0.038), and globus pallidus (p=0.01), but not in the putamen or red nucleus. In contrast, PDDT had higher iron in the nigra (p’s < 0.001), but not other regions, compared to either controls or PDDN. Iron in the nigra increased with disease duration [ PDE > PDDN (p=0.001), PDM > PDE (p=0.045)] except for PDM versus PDL (p=0.226). Levodopa usage was associated with higher (p=0.013) nigral iron, whereas lower nigral iron was correlated with selegiline usage (p= 0.030). Nigral iron is lower prior to the start of dopaminergic medication, and then increases throughout the disease until it plateaus at late stages, suggesting increased iron may not be an etiological factor. Interestingly, PD medications may have differential associations with iron accumulation that are worthy of further investigation.
登录
查看更多内容
DOI：
10.1002/mds.26417
发表时间：
2016-03
期刊：
Movement disorders : official journal of the Movement Disorder Society
影响因子：
--
作者：
Du G;Liu T;Lewis MM;Kong L;Wang Y;Connor J;Mailman RB;Huang X
通讯作者：
Huang X
影响因子：
14.5
作者：
Biondetti, Emma;Gaurav, Rahul;Lehericy, Stephane
通讯作者：
Lehericy, Stephane
影响因子：
4.1
作者：
Giladi, N;Shabtai, H;Korczyn, AD
通讯作者：
Korczyn, AD
影响因子：
5.7
作者：
Langkammer, Christian;Schweser, Ferdinand;Krebs, Nikolaus;Deistung, Andreas;Goessler, Walter;Scheurer, Eva;Sommer, Karsten;Reishofer, Gernot;Yen, Kathrin;Fazekas, Franz;Ropele, Stefan;Reichenbach, Juergen R.
通讯作者：
Reichenbach, Juergen R.
帕金森氏病患者的黑质中，易感性MRI的明显进展模式。
DOI：
10.1002/mds.27318
发表时间：
2018-09
期刊：
Movement disorders : official journal of the Movement Disorder Society
影响因子：
--
作者：
Du G;Lewis MM;Sica C;He L;Connor JR;Kong L;Mailman RB;Huang X
通讯作者：
Huang X